3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
8
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
4
Plasma cell
3
Dermatologic
3
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Head & Neck
1
Breast
1
Conditions
Mesothelioma, Malignant
1
Mesothelioma
1
Interventions
Cisplatin
7
Pemetrexed
6
atezolizumab
5
Carboplatin
4
tislelizumab
3
Paclitaxel
3
Leucovorin
3
Filgrastim
3
Etoposide
3
vistusertib
2
pembrolizumab
2
Vincristine
2
Topotecan
2
Temozolomide
2
Tegafur
2
Sorafenib
2
Irinotecan
2
Immunoenzyme Techniques
2
Gemcitabine
2
Docetaxel
2
Cyclophosphamide
2
zirconium-89-trastuzumab
1
vandetanib
1
toripalimab
1
temsirolimus
1
tanespimycin
1
talazoparib
1
soblidotin
1
selinexor
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Vorinostat
×
Other solid neoplasm
×
Clear all
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn